SEQUOIA研究的新数据将通过两场口头报告展示,凸显百悦泽®用于慢性淋巴细胞白血病(CLL)患者的一线治疗取得获益当前管线产品的早期阶段数据,显现出其用于治疗包括乳腺癌在内的多种实体肿瘤的实力前景数据进一步凸显百泽安®作为独特设计的PD-1抑制剂的有效性及安全性特征美国加州圣卡洛斯——百济神州有限公司(纳斯达克代码:ONC;香港联交所代码:06160;上交所代码:688235)是一家全球肿瘤治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.